Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesBariatric & Obesity ManagementCVS Caremark Wegovy Prior Auth Coverage | OpenPaye…
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy 4774-C

    Initial Prior Authorization with Quantity Limit Wegovy Weight Loss Management

    Customize your policy alerts

    Sign up for cvs_caremark Policy 4774-C alerts

    Get alerted when Policy 4774-C changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs initial and continuation prior authorization, quantity limits, and approval durations for Wegovy products used for chronic weight management, cardiovascular risk reduction, or noncirrhotic MASH in adults and eligible adolescents, subject to indication-specific criteria and product restrictions.

    Policy Summary
    PayerCVS Caremark
    PolicyInitial Prior Authorization with Quantity Limit Wegovy Weight Loss Management
    Policy CodePolicy 4774-C
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization with all indication-specific criteria and required clinical documentation for qualifying Wegovy requests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4Covered indication categories
    12–17Eligible pediatric age range
    BMI ≥30Adult obesity threshold
    BMI ≥27Adult overweight threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    5%
    Continuation weight response
    21/63 daysInjection processing duration

    Coverage Criteria

    Initial therapy - Adult noncirrhotic MASH; Wegovy injection only

    Covered when ALL of the following are met.

    Adult MASH initial therapy

    • Product and treatment requirements: The request is not for Wegovy HD 7.2 mg injection or Wegovy tablets, and the requested drug is used with a reduced-calorie diet and increased physical activity.Wegovy injection only; not Wegovy HD 7.2 mg
    • Prescriber specialty: The requested drug is prescribed by, or in consultation with, a gastroenterologist or hepatologist.
    • Fibrosis confirmation: Baseline moderate to advanced liver fibrosis is confirmed by one of the following: non-invasive liver disease assessment, such as ultrasound-based elastography or magnetic resonance elastography (MRE), or historical liver biopsy.F2 to F3 fibrosis

      Documentation is required for approval.

    Initial therapy - Adult weight reduction or long-term maintenance

    Covered when ALL of the following are met.

    Adult chronic weight management

    • Age: The patient is 18 years of age or older.≥18 years
    • Prior comprehensive program: The patient participated in a comprehensive weight-management program that encourages behavioral modification, reduced-calorie diet, increased physical activity, and continuing follow-up for at least 6 months before drug therapy.≥6 months before drug therapy
    • ONE of

      • Obesity pathway: Baseline BMI is at least 30 kg/m².

    Initial therapy - Pediatric weight reduction or long-term maintenance; Wegovy injection only

    Covered when ALL of the following are met.

    Pediatric chronic weight management

    • Age: The patient is 12 to 17 years of age.12–17 years
    • Product restriction: The request is not for Wegovy HD 7.2 mg injection or Wegovy tablets.Wegovy injection only; not Wegovy HD 7.2 mg
    • Prior comprehensive program: The patient participated in a comprehensive weight-management program that encourages behavioral modification, reduced-calorie diet, increased physical activity, and continuing follow-up for at least 6 months before drug therapy.≥6 months before drug therapy

    Initial therapy - Adult cardiovascular risk reduction

    Covered when ALL of the following are met.

    Adult cardiovascular risk reduction

    • Product and lifestyle requirements: The request is not for Wegovy HD 7.2 mg injection, and the requested drug is used with a reduced-calorie diet and increased physical activity.
    • Established cardiovascular disease: The patient has a history of one of the following: previous myocardial infarction; previous stroke; symptomatic peripheral arterial disease evidenced by intermittent claudication with ankle-brachial index less than 0.85 at rest, peripheral arterial revascularization, or amputation due to atherosclerotic disease; or prior coronary artery bypass grafting, percutaneous coronary intervention, or angioplasty.One qualifying history

      Documentation is required for approval.

    • BMI: Baseline BMI is at least 27 kg/m².

    Continuation therapy - Adult noncirrhotic MASH; Wegovy injection only

    Covered when ALL of the following are met.

    Adult MASH continuation

    • Product and lifestyle requirements: The request is not for Wegovy HD 7.2 mg injection or Wegovy tablets, and the requested drug is used with a reduced-calorie diet and increased physical activity.Wegovy injection only; not Wegovy HD 7.2 mg
    • Positive clinical response: The patient has achieved or maintained a positive clinical response to the requested drug, such as reduced alanine aminotransferase (ALT), improved Enhanced Liver Fibrosis (ELF) score, or improved liver stiffness measurement by ultrasound-based elastography or magnetic resonance elastography (MRE).Positive clinical response

      Documentation is required for approval.

    • Maintenance dose:

    Continuation therapy - Adult weight reduction or long-term maintenance

    Covered when ALL of the following are met.

    Adult chronic weight management continuation

    • Age: The patient is 18 years of age or older.≥18 years
    • Stable therapy duration: The patient has completed at least 3 months of therapy with the requested drug at a stable maintenance dose.≥3 months
    • ONE of

      • Weight loss: The patient has lost at least 5% of baseline body weight.≥5%

    Continuation therapy - Pediatric weight reduction or long-term maintenance; Wegovy injection only

    Covered when ALL of the following are met.

    Pediatric chronic weight management continuation

    • Age: The patient is 12 to 17 years of age.12–17 years
    • Product restriction: The request is not for Wegovy HD 7.2 mg injection or Wegovy tablets.Wegovy injection only; not Wegovy HD 7.2 mg
    • Stable maintenance dose: The patient has successfully titrated to a stable maintenance dose.
    • ONE of

    Continuation therapy - Adult cardiovascular risk reduction

    Covered when ALL of the following are met.

    Adult cardiovascular risk reduction continuation

    • Product and lifestyle requirements: The request is not for Wegovy HD 7.2 mg injection, and the requested drug is used with a reduced-calorie diet and increased physical activity.
    • Established cardiovascular disease: The patient has a history of one of the following: previous myocardial infarction; previous stroke; symptomatic peripheral arterial disease evidenced by intermittent claudication with ankle-brachial index less than 0.85 at rest, peripheral arterial revascularization, or amputation due to atherosclerotic disease; or prior coronary artery bypass grafting, percutaneous coronary intervention, or angioplasty.One qualifying history

      Documentation is required for approval.

    • Maintenance dose: The patient is receiving a maintenance dosage of the requested drug based on individual treatment response and tolerability.

    Wegovy HD 7.2 mg injection is excluded for adult noncirrhotic MASH, pediatric chronic weight management, and adult cardiovascular risk-reduction requests. Wegovy tablets are excluded for adult noncirrhotic MASH and pediatric chronic weight-management requests.

    Concomitant use of Wegovy tablets or injection with another semaglutide-containing product or any other GLP-1 receptor agonist is not recommended.

    Clinical Thresholds and Treatment Parameters

    Adult obesity BMI
    ThresholdBMI ≥30 kg/m²
    PopulationAdults with obesity
    UseQualifies for the adult obesity pathway for chronic weight management
    Adult overweight BMI
    ThresholdBMI ≥27 kg/m²
    Required comorbidityAt least one weight-related comorbid condition
    ExamplesHypertension, type 2 diabetes mellitus, or dyslipidemia

    Authorization and Documentation Requirements

    Prior Authorization

    Indication-Specific Prior Authorization Required

    Prior authorization is required for qualifying requests for Wegovy, including noncirrhotic MASH with F2–F3 fibrosis in adults, chronic weight-management therapy in adults or adolescents, and reduction of major adverse cardiovascular events in qualifying adults.

    • Submit the request under the applicable indication and include all required clinical documentation.
    • Coverage is subject to the indication-specific initial or continuation criteria below.
    Documentation Required

    Document Baseline MASH Fibrosis

    For an adult noncirrhotic MASH request, document baseline moderate to advanced liver fibrosis consistent with stages F2 to F3. Acceptable confirmation is a non-invasive liver disease assessment, such as ultrasound-based elastography or magnetic resonance elastography (MRE), or a historical liver biopsy.

    • Include the fibrosis assessment or biopsy documentation with the request.

    Policy Background

    Wegovy (semaglutide) is used with a reduced-calorie diet and increased physical activity. The policy addresses chronic reduction of excess body weight and long-term maintenance in adults and eligible adolescents, reduction of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis in adults.

    Definitions

    Noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH)
    Current terminologyNoncirrhotic metabolic dysfunction-associated steatohepatitis (MASH)
    Former terminologyFormerly known as nonalcoholic steatohepatitis (NASH)
    Covered fibrosis contextAdults with moderate to advanced liver fibrosis consistent with stages F2 to F3, without cirrhosis
    Major adverse cardiovascular events
    Cardiovascular deathDeath caused by cardiovascular disease
    Non-fatal myocardial infarctionA myocardial infarction that does not result in death
    Non-fatal stroke
    Policy Summary
    PayerCVS Caremark
    PolicyInitial Prior Authorization with Quantity Limit Wegovy Weight Loss Management
    Policy CodePolicy 4774-C
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization with all indication-specific criteria and required clinical documentation for qualifying Wegovy requests.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and Treatment ParametersAuthorization and Documentation RequirementsPolicy BackgroundDefinitions
    ≥30 kg/m²

    Documentation is required for approval.

  1. Overweight with comorbidity pathway: Baseline BMI is at least 27 kg/m² and the patient has at least one weight-related comorbid condition, such as hypertension, type 2 diabetes mellitus, or dyslipidemia.≥27 kg/m² plus ≥1 comorbidity

    Documentation is required for approval.

  2. Pediatric BMI: Baseline BMI is at or above the 95th percentile standardized for age and sex.≥95th percentile

    Documentation is required for approval.

  3. ≥27 kg/m²

    When transitioning from another weight-loss drug, use baseline BMI at the start of any drug therapy. Documentation is required for approval.

  4. Diabetes status: The patient does not have type 2 diabetes.No type 2 diabetes
  5. ONE of

    • Receiving GDMT: The patient is currently receiving guideline-directed management and therapy, such as a lipid-lowering agent, antiplatelet, beta-blocker, or renin-angiotensin inhibitor.
    • Reason not to use GDMT: The patient has a clinical reason not to be treated with GDMT for cardiovascular disease.

      Documentation is required for approval.

  6. The patient is receiving a maintenance dosage of the requested drug based on individual treatment response and tolerability.
  7. Weight-loss maintenance: The patient has continued to maintain the initial 5% weight loss.Maintain initial ≥5% loss
  8. BMI reduction: The patient has had a reduction from baseline BMI.
  9. BMI-reduction maintenance: The patient has continued to maintain the initial BMI reduction.
  10. Pediatric obesity BMI
    ThresholdBMI at or above the 95th percentile
    StandardizationStandardized for age and sex
    PopulationPediatric patients ages 12 to 17 years
    Pediatric age
    Eligible age range12 to 17 years
    IndicationPediatric reduction in excess body weight or long-term maintenance of weight reduction
    Product restrictionWegovy injection only; Wegovy HD 7.2 mg injection and Wegovy tablets are excluded
    Prior comprehensive weight-management program
    Required durationAt least 6 months before drug therapy
    Program elementsBehavioral modification, reduced-calorie diet, and increased physical activity
    Follow-upContinuing follow-up is required during the comprehensive weight-management program
    Peripheral arterial disease ABI
    ABI thresholdLess than 0.85 at rest
    ConditionSymptomatic peripheral arterial disease
    Clinical findingIntermittent claudication may establish symptomatic PAD when the qualifying ABI is present
    Adult continuation weight response
    Stable-dose durationAt least 3 months of therapy with the requested drug at a stable maintenance dose
    Weight responseLoss of at least 5% of baseline body weight
    Alternative responseContinued maintenance of the initial 5% weight loss
    MASH fibrosis stage
    Required fibrosis stageF2 to F3 fibrosis
    SeverityModerate to advanced liver fibrosis
    Disease contextNoncirrhotic metabolic dysfunction-associated steatohepatitis in adults
  11. The drug must be prescribed by, or in consultation with, a gastroenterologist or hepatologist.
  12. Documentation Required

    Document Baseline BMI and Comorbidities

    Document the baseline BMI and applicable weight-management history for adult requests. If the patient is transitioning from another weight-loss drug, use the BMI and comorbidities at the start of any drug therapy as the transition baseline.

    • Adult baseline BMI must be at least 30 kg/m², or at least 27 kg/m² with at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or dyslipidemia.
    • Document participation in a comprehensive weight-management program involving behavioral modification, a reduced-calorie diet, increased physical activity, and continuing follow-up for at least 6 months before drug therapy.
    • Document the qualifying comorbidity when the baseline BMI is at least 27 kg/m².

    Unsupported block type: documentation

    Unsupported block type: documentation

    Denial Risk

    Verify Covered Product and Formulation

    Requests may be denied when the product or formulation is excluded for the requested indication. Confirm that the prescribed formulation matches the covered indication before submitting the request.

    • Adult and pediatric weight-management requests, and MASH requests, must not be for Wegovy HD 7.2 mg injection or Wegovy semaglutide tablets.
    • Cardiovascular risk-reduction requests must not be for Wegovy HD 7.2 mg injection.
    • MASH coverage is for Wegovy injection only, excluding Wegovy HD 7.2 mg injection; pediatric weight-management coverage is also for Wegovy injection only, excluding Wegovy HD 7.2 mg injection.
    Denial Risk

    Avoid Concurrent GLP-1 or Semaglutide Therapy

    Concomitant use of Wegovy semaglutide tablets or injection with another semaglutide-containing product or any other GLP-1 receptor agonist is not recommended and may prevent approval.

    • Review the medication list for concurrent GLP-1 receptor agonist therapy or another semaglutide-containing product.
    • Document discontinuation or non-use of conflicting therapy when submitting the request, as applicable.
    Denial Risk

    Meet Indication-Specific Clinical Criteria

    Requests may be denied when indication-specific clinical requirements are not met, including age, BMI, comorbidity, cardiovascular-disease, diabetes-exclusion, or pediatric BMI requirements.

    • Adult weight management: patient must be at least 18 years old and meet the applicable BMI threshold, with a qualifying comorbidity when BMI is at least 27 kg/m².
    • Pediatric weight management: patient must be 12 to 17 years old and have a baseline BMI at or above the 95th percentile standardized for age and sex.
    • Cardiovascular risk reduction: patient must be an adult with established cardiovascular disease, baseline BMI of at least 27 kg/m², and no type 2 diabetes.
    • MASH: patient must be an adult with noncirrhotic MASH and baseline F2 to F3 fibrosis.
    Denial Risk

    Document Required Treatment and Response

    Coverage may be denied when required treatment conditions or continuation response are absent. The requested drug must be used with a reduced-calorie diet and increased physical activity, and applicable weight-management participation and response requirements must be documented.

    • Initial MASH, adult weight-management, pediatric weight-management, and cardiovascular requests require use with a reduced-calorie diet and increased physical activity.
    • Initial adult and pediatric weight-management requests require at least 6 months of comprehensive weight-management participation with behavioral modification, diet, physical activity, and follow-up before drug therapy.
    • Continuation adult weight-management requests require at least 5% weight loss or maintenance of the initial 5% loss after at least 3 months at a stable maintenance dose.
    • Continuation pediatric requests require BMI reduction or maintenance of the initial BMI reduction; continuation MASH requests require positive clinical response; continuation cardiovascular requests require maintenance dosing based on response and tolerability.
    A stroke that does not result in death
    Established cardiovascular disease
    Prior eventsPrevious myocardial infarction or previous stroke
    Peripheral arterial diseaseSymptomatic PAD evidenced by intermittent claudication with ABI less than 0.85 at rest, peripheral arterial revascularization, or amputation due to atherosclerotic disease
    Revascularization historyPrior coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), or angioplasty
    Guideline-directed management and therapy
    Qualifying therapiesLipid-lowering agent, antiplatelet, beta-blocker, or renin-angiotensin inhibitor
    PurposeManagement of cardiovascular disease
    Alternative qualificationA documented clinical reason not to receive guideline-directed management and therapy